Summary of ProstaLund's historical development
2018 - 2019

ProstaLund changed the stock market from the spotlight to Nasdaq First North Growth Market.

The Specialty Council in Urology in the Stockholm Region highlights TUMT (transurethral microwave therapy, CoreTherm®) as a well-established and evidence-based minimally invasive treatment that is well suited for outpatient setting.

The County Hospital in Kalmar shows in a long-term follow-up that CoreTherm® patients have as good long-term results as those who have had surgery. CoreTherm® is increasingly accepted within the urology society in the Nordic countries.

Agreements are signed with Norway's largest private urology clinic.

The first treatments are carried out in Iran.


ProstaLund's Board of Directors appoints Hans Östlund as CEO of the company as of 1 June 2016.


Magnus Bolmsjö, founder of ProstaLund and its CEO between the years 2003 - 2006 are engaged by the new owners to lead the restart and move to Lund. Focus on building the sales organization. The company also initiated research to investigate CoreTherm's effect on prostate cancer.


The owners and the board who were responsible for the move

to Uppsala leaves the company. New big owners will be

Bo Håkansson and William Gunnarsson.


New ownership structure, management and board move operations from Lund to Uppsala.


Start-up of own sales company in Orlando, USA.


Agreement signed with distributor Shaanxi Yuandaolong Medical Technologies Co Ltd. (China) with an initial million order.


FDA approval and start of operations in the USA.

Agreement concluded with major US distributor for the USA.


The company is founded by Associate Professor Magnus Bolmsjö in Lund.